Home Cart Sign in  
Chemical Structure| 1448584-12-0 Chemical Structure| 1448584-12-0

Structure of S55746
CAS No.: 1448584-12-0

Chemical Structure| 1448584-12-0

*Storage: {[sel_prStorage]}

*Shipping: {[sel_prShipping]}

,{[proInfo.pro_purity]}

S55746 is a potent and selective inhibitor of the anti-apoptotic protein B-cell lymphoma 2 (Bcl-2), with potential pro-apoptotic and antineoplastic activities.

Synonyms: BCL201

4.5 *For Research Use Only !

{[proInfo.pro_purity]}
Cat. No.: {[proInfo.prAm]} Purity: {[proInfo.pro_purity]}

Change View

Size Price VIP Price

US Stock

Global Stock

In Stock
{[ item.pr_size ]} Inquiry {[ getRatePrice(item.pr_usd,item.pr_rate,item.mem_rate,item.pr_is_large_size_no_price, item.vip_usd) ]}

US Stock: ship in 0-1 business day
Global Stock: ship in 5-7 days

  • {[ item.pr_size ]}

In Stock

- +

Please Login or Create an Account to: See VIP prices and availability

US Stock: ship in 0-1 business day
Global Stock: ship in 2 weeks

  • 1-2 Day Shipping
  • High Quality
  • Technical Support
Product Citations

Alternative Products

Product Details of S55746

CAS No. :1448584-12-0
Formula : C43H42N4O6
M.W : 710.82
SMILES Code : O=C(C1=C2CCCCN2C(C3=C(C(N4CC5=C(C=CC=C5)C[C@H]4CN6CCOCC6)=O)C=C(OCO7)C7=C3)=C1)N(C8=CC=C(O)C=C8)C9=CC=CC=C9
Synonyms :
BCL201
MDL No. :MFCD31715456

Safety of S55746

GHS Pictogram:
Signal Word:Warning
Hazard Statements:H302-H315-H319-H335
Precautionary Statements:P261-P305+P351+P338

Isoform Comparison

Biological Activity

In Vitro:

Cell Line
Concentration Treated Time Description References
HL60 0.01 to 6.7 µM (IC50) 72 hours To evaluate the anti-leukemic effect of S55746 alone or in combination with CalPegA. Results showed that CalPegA enhanced the anti-leukemic effect of S55746, reducing the IC50 by approximately 4- to 5-fold. PMC11641566
MV411 0.01 to 6.7 µM (IC50) 72 hours To evaluate the anti-leukemic effect of S55746 alone or in combination with CalPegA. Results showed that CalPegA enhanced the anti-leukemic effect of S55746, reducing the IC50 by approximately 4- to 5-fold. PMC11641566
MonoMac6 0.01 to 6.7 µM (IC50) 72 hours To evaluate the anti-leukemic effect of S55746 alone or in combination with CalPegA. Results showed that CalPegA enhanced the anti-leukemic effect of S55746, reducing the IC50 by approximately 4- to 5-fold. PMC11641566
MOLM14 0.01 to 6.7 µM (IC50) 72 hours To evaluate the anti-leukemic effect of S55746 alone or in combination with CalPegA. Results showed that CalPegA enhanced the anti-leukemic effect of S55746, reducing the IC50 by approximately 4- to 5-fold. PMC11641566
Chondrosarcoma cell lines 0-1000 nM 72 hours Evaluate the effect of selective Bcl-2 inhibition on chondrosarcoma cell lines, results showed chondrosarcoma cell lines were not sensitive to S55746 PMC6155044

In Vivo:

Species
Animal Model
Administration Dosage Frequency Description References
NRG mice MV411-luc and AML45-luc xenograft models Oral gavage 75 mg/kg 5 times per week To evaluate the anti-leukemic effect of S55746 alone or in combination with CalPegA. Results showed that the S55746-CalPegA combination reduced tumor burden more effectively than either single agent. PMC11641566
NOD/SCID/IL2rγnull mice MV4;11 and OCI-AML3 xenograft models Oral and intravenous S55746 100 mg/kg + S63845 25 mg/kg S55746 once daily for 5 days/week for 4 weeks; S63845 twice weekly for 4 weeks Evaluate the anti-leukemic activity of S55746 in combination with S63845, showing significant prolongation of survival and suppression of leukemia cell growth PMC6484700

Clinical Trial:

NCT Number Conditions Phases Recruitment Completion Date Locations
NCT02603445 Follicular Lymphoma, Mantle Ce... More >>ll Lymphoma Less << Phase 1 Completed - United States, New York ... More >> Novartis Investigative Site New York, New York, United States, 10017 United States, Texas Novartis Investigative Site Houston, Texas, United States, 77030 Austria Novartis Investigative Site Salzburg, Austria, 5020 France Novartis Investigative Site Pierre-Benite Cedex, France, 69495 Novartis Investigative Site Toulouse Cedex 9, France, 31059 Germany Novartis Investigative Site Freiburg, Germany, 79106 Novartis Investigative Site Mainz, Germany, 55131 Less <<
NCT02920697 Chronic Lymphocytic Leukaemia ... More >>(CLL) B-Cell Non-Hodgkin Lymphoma (NHL) Multiple Myeloma (MM) Less << Phase 1 Completed - Australia ... More >> The Alfred Hospital Malignant Haematology & Stem Cell Transplantation Services Melbourne, Australia, 3004 France Hopital Claude Huriez Lille, France CHU de Nantes Nantes, France Centre hospitalier Lyon Sud Pierre-Bénite, France Gustave Roussy Villejuif, France Germany Universitätsklinikum Carl Gustav Carus Dresden, Germany Städtisches Klinikum Schwabing Munich, Germany Universitätsklinikum Ulm Ulm, Germany Hungary National Oncology Institute Budapest, Hungary CRU Hungary Kft Miskolc, Hungary Korea, Republic of Severance Hospital Seoul, Korea, Republic of St. Mary's Hospital Seoul, Korea, Republic of Poland Warsaw Institute of Oncology Warsaw, Poland Warsaw Medical University Warsaw, Poland Singapore National Cancer Center (NCC) Singapore, Singapore National University Cancer Institute Singapore Singapore, Singapore United Kingdom University College London Hospitals London, United Kingdom Freeman Hospital Newcastle, United Kingdom Less <<

Protocol

Bio Calculators
Preparing Stock Solutions 1mg 5mg 10mg

1 mM

5 mM

10 mM

1.41mL

0.28mL

0.14mL

7.03mL

1.41mL

0.70mL

14.07mL

2.81mL

1.41mL

References

 

Historical Records

Categories